| 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 肝病类(元) | 235,345,216.08 | 160,477,916.75 | 180,409,379.23 | 89,169,728.25 |
| 呼吸系统类(元) | - | - | 3,982,963.73 | 3,982,963.73 |
| 技术服务费(元) | 34,942,861.04 | 17,421,334.67 | 31,809,540.36 | 7,143,215.33 |
| 抗菌类(元) | 151,727,487.08 | 73,094,038.33 | 83,847,142.68 | 29,500,165.70 |
| 抗肿瘤类(元) | 1,702,992.45 | 107,008.14 | 2,570,588.66 | 1,846,996.56 |
| 前列腺素类(元) | 26,463,594.18 | 13,518,060.71 | 19,056,954.06 | 10,725,746.05 |
| 神经系统类(元) | 12,503,667.71 | 3,221,250.08 | 123,063,479.72 | 63,649,968.00 |
| 痛风类(元) | 92,220,264.42 | 54,970,519.87 | 71,564,138.39 | 40,491,585.53 |
| 心脑血管类(元) | 165,649,008.94 | 86,931,243.44 | 191,151,922.60 | 38,772,153.22 |
| 高端氟产品(元) | 2,052,981.59 | 2,020,114.81 | 2,297,399.60 | 2,067,666.84 |
| 其他主营业务(元) | - | - | - | 2,067,666.84 |
| 其他类(元) | 94,157,009.78 | 56,954,125.62 | 54,793,880.01 | 94,010,354.66 |
| 营业成本(元) | ||||
| 肝病类(元) | 64,571,503.55 | - | 54,230,128.88 | - |
| 呼吸系统类(元) | - | - | 3,193,304.38 | - |
| 技术服务费(元) | 15,590,361.30 | - | 13,426,737.23 | - |
| 抗菌类(元) | 76,050,521.34 | - | 37,568,195.86 | - |
| 抗肿瘤类(元) | 727,332.18 | - | 1,697,456.04 | - |
| 前列腺素类(元) | 3,980,913.57 | - | 1,617,377.88 | - |
| 神经系统类(元) | 6,980,112.71 | - | 78,036,752.96 | - |
| 痛风类(元) | 59,221,046.39 | - | 51,302,299.92 | - |
| 心脑血管类(元) | 100,443,195.42 | - | 110,675,110.40 | - |
| 高端氟产品(元) | 460,424.38 | - | 599,170.44 | - |
| 其他主营业务(元) | - | - | - | - |
| 其他类(元) | 39,125,945.31 | - | 18,448,341.53 | - |
| 毛利(元) | ||||
| 肝病类(元) | 170,773,712.53 | - | 126,179,250.35 | - |
| 呼吸系统类(元) | - | - | 789,659.35 | - |
| 技术服务费(元) | 19,352,499.74 | - | 18,382,803.13 | - |
| 抗菌类(元) | 75,676,965.74 | - | 46,278,946.82 | - |
| 抗肿瘤类(元) | 975,660.27 | - | 873,132.62 | - |
| 前列腺素类(元) | 22,482,680.61 | - | 17,439,576.18 | - |
| 神经系统类(元) | 5,523,555.00 | - | 45,026,726.76 | - |
| 痛风类(元) | 32,999,218.03 | - | 20,261,838.47 | - |
| 心脑血管类(元) | 65,205,813.52 | - | 80,476,812.20 | - |
| 高端氟产品(元) | 1,592,557.21 | - | 1,698,229.16 | - |
| 其他主营业务(元) | - | - | - | - |
| 其他类(元) | 55,031,064.47 | - | 36,345,538.48 | - |
| 毛利率(%) | ||||
| 肝病类(%) | 72.56 | - | 69.94 | - |
| 呼吸系统类(%) | - | - | 19.83 | - |
| 技术服务费(%) | 55.38 | - | 57.79 | - |
| 抗菌类(%) | 49.88 | - | 55.19 | - |
| 抗肿瘤类(%) | 57.29 | - | 33.97 | - |
| 前列腺素类(%) | 84.96 | - | 91.51 | - |
| 神经系统类(%) | 44.18 | - | 36.59 | - |
| 痛风类(%) | 35.78 | - | 28.31 | - |
| 心脑血管类(%) | 39.36 | - | 42.10 | - |
| 高端氟产品(%) | 77.57 | - | 73.92 | - |
| 其他主营业务(%) | - | - | - | - |
| 其他类(%) | 58.45 | - | 66.33 | - |
| 收入构成(%) | ||||
| 肝病类(%) | 28.81 | 34.24 | 23.60 | 23.26 |
| 呼吸系统类(%) | - | - | 0.52 | 1.04 |
| 技术服务费(%) | 4.28 | 3.72 | 4.16 | 1.86 |
| 抗菌类(%) | 18.58 | 15.59 | 10.97 | 7.69 |
| 抗肿瘤类(%) | 0.21 | 0.02 | 0.34 | 0.48 |
| 前列腺素类(%) | 3.24 | 2.88 | 2.49 | 2.80 |
| 神经系统类(%) | 1.53 | 0.69 | 16.10 | 16.60 |
| 痛风类(%) | 11.29 | 11.73 | 9.36 | 10.56 |
| 心脑血管类(%) | 20.28 | 18.55 | 25.00 | 10.11 |
| 高端氟产品(%) | 0.25 | 0.43 | 0.30 | 0.54 |
| 其他主营业务(%) | - | - | - | 0.54 |
| 其他类(%) | 11.53 | 12.15 | 7.17 | 24.52 |
| 毛利构成(%) | ||||
| 肝病类(%) | 37.98 | - | 32.05 | - |
| 呼吸系统类(%) | - | - | 0.20 | - |
| 技术服务费(%) | 4.30 | - | 4.67 | - |
| 抗菌类(%) | 16.83 | - | 11.75 | - |
| 抗肿瘤类(%) | 0.22 | - | 0.22 | - |
| 前列腺素类(%) | 5.00 | - | 4.43 | - |
| 神经系统类(%) | 1.23 | - | 11.44 | - |
| 痛风类(%) | 7.34 | - | 5.15 | - |
| 心脑血管类(%) | 14.50 | - | 20.44 | - |
| 高端氟产品(%) | 0.35 | - | 0.43 | - |
| 其他主营业务(%) | - | - | - | - |
| 其他类(%) | 12.24 | - | 9.23 | - |